Constitutive Activation of the Angiotensin II Type 1 Receptor Alters the Spatial Proximity of Transmembrane 7 to the Ligand-binding Pocket*

Activation of G protein-coupled receptors by agonists involves significant movement of transmembrane domains (TM) following binding of agonist. The underlying structural mechanism by which receptor activation takes place is largely unknown but can be inferred by detecting variability within the environment of the ligand-binding pocket, which constitutes a water-accessible crevice surrounded by the seven TM helices. Using the substituted cysteine accessibility method, we initially identified those residues within the seventh transmembrane domain (TM7) of wild type angiotensin II type 1 (AT1) receptor that contribute to forming the binding site pocket. We have substituted successively TM7 residues ranging from Ile276 to Tyr302 to cysteine. Treatment of A277C, V280C, T282C, A283C, I286C, A291C, and F301C mutant receptors with the charged sulfhydryl-specific alkylating agent MTSEA significantly inhibited ligand binding, which suggests that these residues orient themselves within the water-accessible binding pocket of the AT1 receptor. Interestingly, this pattern of acquired MTSEA sensitivity was greatly reduced for TM7 reporter cysteines engineered in a constitutively active mutant of the AT1 receptor. Our data suggest that upon activation, TM7 of the AT1 receptor goes through a pattern of helical movements that results in its distancing from the binding pocket per se. These studies support accumulating evidence whereby elements of TM7 of class A GPCRs promote activation of the receptor through structural rearrangements.

[1]  T. Inagami,et al.  A review of mutagenesis studies of angiotensin II type 1 receptor, the three‐dimensional receptor model in search of the agonist and antagonist binding site and the hypothesis of a receptor activation mechanism , 1997, Journal of hypertension.

[2]  H A Scheraga,et al.  A computer modeling postulated mechanism for angiotensin II receptor activation , 1995, Journal of protein chemistry.

[3]  S. Karnik,et al.  Role of Transmembrane Helix IV in G-protein Specificity of the Angiotensin II Type 1 Receptor* , 1999, The Journal of Biological Chemistry.

[4]  L. Hunyady,et al.  Dependence of AT1 angiotensin receptor function on adjacent asparagine residues in the seventh transmembrane helix. , 1998, Molecular pharmacology.

[5]  X. P. Liu,et al.  The active state of the AT1 angiotensin receptor is generated by angiotensin II induction. , 1996, Biochemistry.

[6]  J. Javitch,et al.  A cysteine residue in the third membrane-spanning segment of the human D2 dopamine receptor is exposed in the binding-site crevice. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[7]  P Ghanouni,et al.  Mutation of a highly conserved aspartic acid in the beta2 adrenergic receptor: constitutive activation, structural instability, and conformational rearrangement of transmembrane segment 6. , 1999, Molecular pharmacology.

[8]  S. Miura,et al.  TM2-TM7 Interaction in Coupling Movement of Transmembrane Helices to Activation of the Angiotensin II Type-1 Receptor* , 2003, The Journal of Biological Chemistry.

[9]  D. Farrens,et al.  Conformational Changes in Rhodopsin , 1999, The Journal of Biological Chemistry.

[10]  S. Miura,et al.  Constitutive Activation of Angiotensin II Type 1 Receptor Alters the Orientation of Transmembrane Helix-2* , 2002, The Journal of Biological Chemistry.

[11]  T. Inagami,et al.  Disulfide bridges in extracellular domains of angiotensin II receptor type IA , 1995, Regulatory Peptides.

[12]  J. Klein-Seetharaman,et al.  Structure and function in rhodopsin: mapping light-dependent changes in distance between residue 316 in helix 8 and residues in the sequence 60-75, covering the cytoplasmic end of helices TM1 and TM2 and their connection loop CL1. , 2001, Biochemistry.

[13]  B. Kobilka,et al.  G Protein-coupled Receptors , 1998, The Journal of Biological Chemistry.

[14]  R. Leduc,et al.  Residues 293 and 294 are ligand contact points of the human angiotensin type 1 receptor. , 2002, Biochemistry.

[15]  J. Wess,et al.  Use of an in situ disulfide cross-linking strategy to map proximities between amino acid residues in transmembrane domains I and VII of the M3 muscarinic acetylcholine receptor. , 2002, Biochemistry.

[16]  R. Leduc,et al.  Photolabeling identifies position 172 of the human AT(1) receptor as a ligand contact point: receptor-bound angiotensin II adopts an extended structure. , 2000, Biochemistry.

[17]  R. Leduc,et al.  Photolabelling the rat urotensin II/GPR14 receptor identifies a ligand-binding site in the fourth transmembrane domain. , 2003, The Biochemical journal.

[18]  O. Lichtarge,et al.  Rhodopsin activation blocked by metal-ion-binding sites linking transmembrane helices C and F , 1996, Nature.

[19]  R. Leduc,et al.  The tyrosine within the NPXnY motif of the human angiotensin II type 1 receptor is involved in mediating signal transduction but is not essential for internalization. , 1996, Molecular pharmacology.

[20]  G. Liapakis,et al.  Use of the substituted cysteine accessibility method to study the structure and function of G protein-coupled receptors. , 2002, Methods in enzymology.

[21]  K. Palczewski,et al.  Crystal Structure of Rhodopsin: A G‐Protein‐Coupled Receptor , 2002, Chembiochem : a European journal of chemical biology.

[22]  E. Dawson,et al.  Determination of amino acid residues that are accessible from the ligand binding crevice in the seventh transmembrane-spanning region of the human A(1) adenosine receptor. , 2001, Molecular pharmacology.

[23]  Krzysztof Palczewski,et al.  Role of the conserved NPxxY(x)5,6F motif in the rhodopsin ground state and during activation , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[24]  L. Hunyady,et al.  The ligand binding site of the angiotensin AT1 receptor. , 1996, Trends in pharmacological sciences.

[25]  G. Liapakis,et al.  Constitutive Activation of the β2 Adrenergic Receptor Alters the Orientation of Its Sixth Membrane-spanning Segment* , 1997, The Journal of Biological Chemistry.

[26]  R. Seifert,et al.  Constitutive activity of G-protein-coupled receptors: cause of disease and common property of wild-type receptors , 2002, Naunyn-Schmiedeberg's Archives of Pharmacology.

[27]  Harel Weinstein,et al.  Conserved Helix 7 Tyrosine Acts as a Multistate Conformational Switch in the 5HT2C Receptor , 2002, The Journal of Biological Chemistry.

[28]  A. Kowalski-Chauvel,et al.  Mutation of Asn-391 within the Conserved NPXXY Motif of the Cholecystokinin B Receptor Abolishes Gq Protein Activation without Affecting Its Association with the Receptor* , 2000, The Journal of Biological Chemistry.

[29]  W. Greenlee,et al.  Identification of peptide binding residues in the extracellular domains of the AT1 receptor. , 1994, The Journal of biological chemistry.

[30]  P Ghanouni,et al.  Agonist-induced conformational changes in the G-protein-coupling domain of the β2 adrenergic receptor , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[31]  H. Khorana,et al.  Requirement of Rigid-Body Motion of Transmembrane Helices for Light Activation of Rhodopsin , 1996, Science.

[32]  J. Ballesteros,et al.  [19] Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors , 1995 .

[33]  L. Hunyady,et al.  Angiotensin IV Is a Potent Agonist for Constitutive Active Human AT1 Receptors , 2002, The Journal of Biological Chemistry.

[34]  P. Fraker,et al.  Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril. , 1978, Biochemical and biophysical research communications.

[35]  L. Hunyady,et al.  A Conserved NPLFY Sequence Contributes to Agonist Binding and Signal Transduction but Is Not an Internalization Signal for the Type 1 Angiotensin II Receptor (*) , 1995, The Journal of Biological Chemistry.

[36]  T. Sakmar,et al.  Rhodopsin: structural basis of molecular physiology. , 2001, Physiological reviews.

[37]  D. Osguthorpe,et al.  Structure and energetics of ligand binding to proteins: Escherichia coli dihydrofolate reductase‐trimethoprim, a drug‐receptor system , 1988, Proteins.

[38]  K. Catt,et al.  International union of pharmacology. XXIII. The angiotensin II receptors. , 2000, Pharmacological reviews.

[39]  J. Klein-Seetharaman,et al.  Structure and function in rhodopsin: mapping light-dependent changes in distance between residue 65 in helix TM1 and residues in the sequence 306-319 at the cytoplasmic end of helix TM7 and in helix H8. , 2001, Biochemistry.

[40]  J. Ballesteros,et al.  Residues in the seventh membrane-spanning segment of the dopamine D2 receptor accessible in the binding-site crevice. , 1996, Biochemistry.

[41]  B. Maigret,et al.  Tyr292 in the seventh transmembrane domain of the AT1A angiotensin II receptor is essential for its coupling to phospholipase C. , 1994, The Journal of biological chemistry.